{
    "nct_id": "NCT03639246",
    "official_title": "A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer",
    "inclusion_criteria": "* Age 18 years or older\n* Histologically confirmed and documented recurrent ovarian, fallopian tube, and peritoneal cancer.\n* Platinum resistant disease, defined as progression within â‰¤ 6 months from completion of most recent regimen and calculated from the date of the last administered dose of platinum therapy\n* Must have available archived tumor tissue OR if archived tissue is not available, willing to provide a fresh tumor biopsy\n* Must have radiologic imaging with a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within 4 weeks of first dose of study drug\n* Received at least 1 but not more than 3 therapy regimens, not including maintenance or adjuvant therapy\n* Must have ovarian cancer that is measurable according to RECIST 1.1\n* ECOG performance status of 0-1\n* Normal gastrointestinal (GI), bone marrow, liver and kidney function\n* At least 28 days between termination of prior anti-cancer or hormonal therapy and administration of AVB-S6-500\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Primary platinum-refractory disease (defined as progression during the first platinum regimen or within 4 weeks of completion of the first platinum regimen)\n* Currently being treated with concurrent anti-cancer therapy or any other interventional treatment or trial\n* Received prior therapy with Pac or PLD in the recurrent setting, depending on physician-chosen chemotherapy for this study\n* Significant cardiac disease history\n* Has other prior or concurrent malignancy within the past 5 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix\n* Symptomatic CNS metastasis or metastases\n* Serious active infection requiring IV antibiotics and/or hospitalization at study entry\n* Has known previous or current human immune deficiency (HIV) syndrome, hepatitis B, or hepatitis C\n* Has had paracentesis for ascites within 3 months",
    "miscellaneous_criteria": ""
}